TOVALT ODT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOVALT ODT (TOVALT ODT).
Tovalt ODT (selegiline) is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). At therapeutic doses, it inhibits MAO-B more selectively than MAO-A, leading to increased levels of dopamine in the brain.
| Metabolism | Metabolized primarily by CYP2B6 and CYP3A4 to N-desmethylselegiline, L-amphetamine, and L-methamphetamine. Other minor pathways include CYP2C19 and CYP2D6. |
| Excretion | Primarily hepatic metabolism; 70–80% as inactive metabolites in urine, <5% unchanged in urine, 20–30% fecal. |
| Half-life | Terminal elimination half-life approximately 40–60 hours after multiple dosing; clinical context: reaches steady-state after 2–3 weeks. |
| Protein binding | ~96% bound predominantly to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd ~1.5 L/kg, indicating extensive tissue distribution; large Vd suggests high lipophilicity. |
| Bioavailability | Sublingual: ~90% compared to oral due to avoidance of first-pass metabolism. |
| Onset of Action | Sublingual: detectable plasma levels within 10–15 minutes; peak clinical effect (anxiety relief) within 1–2 hours. |
| Duration of Action | Duration of anxiolytic effect ~7–8 hours after single dose; may persist longer with chronic dosing due to accumulation. |
| Molecular Weight | 144.21 Da |
20 mg sublingually as needed for BTP, with a minimum interval of 2 hours between doses; maximum 4 doses per day.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | For GFR 30-89 mL/min: no adjustment. For GFR <30 mL/min: initiate with 50% of usual dose and titrate cautiously due to increased fentanyl exposure. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: initiate with 50% of usual dose and titrate cautiously. Child-Pugh C: not recommended as metabolism is severely impaired. |
| Pediatric use | Not recommended for use in pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | Initiate at 50% of usual adult dose (10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression. |
| 1st trimester | Avoid use during first trimester; potential teratogenic effects (limb defects, craniofacial anomalies) based on animal studies and class effect of valproate. |
| 2nd trimester | Use only if benefit outweighs risk; increased risk of major congenital malformations and neurodevelopmental deficits. |
| 3rd trimester | Avoid use; risk of neonatal bleeding (hypofibrinogenemia), hepatic toxicity, and withdrawal symptoms. |
Clinical note
Comprehensive clinical and safety monograph for TOVALT ODT (TOVALT ODT).
| Placental transfer | Valproic acid crosses the placenta with cord blood concentrations 1-2 times maternal serum. Transfers via passive diffusion and active transporters. |
| Breastfeeding | Valproic acid is excreted into breast milk at low concentrations (1-10% of maternal serum). Monitor infant for hepatotoxicity, thrombocytopenia, and drowsiness. Generally considered compatible with breastfeeding, but caution in combination with other anticonvulsants or if infant is jaundiced. |
■ FDA Black Box Warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS; Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors.
| Serious Effects |
Hypersensitivity to valproate or any componentHepatic disease or significant hepatic dysfunctionUrea cycle disorders (e.g., ornithine transcarbamylase deficiency)Known mitochondrial disorder (e.g., Alpers-Huttenlocher syndrome) caused by POLG mutationsPorphyria
| Precautions | Risk of hypertensive crisis with tyramine-rich foods or concomitant use of other MAOIs, serotonergic drugs, or sympathomimetics. May cause serotonin syndrome, exacerbation of Parkinson's disease, orthostatic hypotension, and impulse control disorders. Do not exceed recommended dose due to loss of MAO-B selectivity. |
| Food/Dietary | No significant food interactions. Grapefruit juice does not alter rizatriptan metabolism. However, alcohol may exacerbate migraine symptoms and should be avoided during an attack. |
Loading safety data…
| Lactation Rating | L3: Moderately Safe |
| Teratogenic Risk | Pregnancy Category X. Tovalt ODT (topiramate) is contraindicated in pregnancy due to increased risk of oral clefts (cleft lip/palate) and other congenital malformations (e.g., neural tube defects, hypospadias) when exposed during first trimester. Exposure in second/third trimester may be associated with decreased fetal growth, microcephaly, and neurodevelopmental impairments. Use effective contraception. |
| Fetal Monitoring | Monitor serum topiramate levels (therapeutic range 5-20 mcg/mL) every 1-3 months and adjust dose to maintain trough levels. Assess fetal growth via ultrasound every 4-6 weeks. Perform detailed fetal anatomy ultrasound at 18-22 weeks gestation. Monitor for signs of preeclampsia, gestational diabetes, and fetal distress. Postnatal surveillance for developmental milestones. |
| Fertility Effects | Topiramate may impair fertility in females by causing menstrual cycle irregularities and anovulation, possibly due to weight loss or hormonal effects. In males, no established effects on spermatogenesis or fertility, but data limited. Advise women of childbearing potential to use reliable contraception. |
| Clinical Pearls | TOVALT ODT is an oral disintegrating tablet of rizatriptan, a selective 5-HT1B/1D receptor agonist for acute migraine. Onset of action within 30 minutes. Avoid in patients with ischemic heart disease, uncontrolled hypertension, or hemiplegic/basilar migraine. Do not exceed 30 mg in 24 hours. If first dose ineffective, second dose unlikely to help. Use with caution in patients with known risk factors for coronary artery disease. Monitor for serotonin syndrome when combined with other serotonergic drugs. |
| Patient Advice | Take one tablet at the first sign of migraine headache. Do not take more than 30 mg in 24 hours. · Place the tablet on the tongue where it will dissolve without water. Do not crush or chew. · If migraine does not improve after first dose, do not take a second dose for the same attack. · Seek emergency care if you experience chest pain, shortness of breath, or irregular heartbeat after taking this medication. · Inform your doctor if you have a history of heart disease, high blood pressure, stroke, or liver/kidney disease. · Avoid taking within 24 hours of another triptan or ergotamine-containing medication. · This medication is for acute treatment only, not for prevention of migraines. |